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Cleveland, OhioFIGURE 1. Sapien valve seated several millimeters within Mosaic valve
after circular radiopaque markers.Reoperation purely for right-sided heart failure with
tricuspid valve disease carries an increased risk of death.
We describe a patient who underwent percutaneous
tricuspid valve-in-valve insertion via transfemoral and
transjugular approaches.
CASE DESCRIPTION
The patient is an 80-year-old woman with a history of
rheumatic heart disease requiring mitral valve replacement
34 years before presentation with a Bjork-Shiley valve.
Seven years before presentation, she underwent tricuspid
valve replacement with a no. 27 Medtronic Mosaic valve
along with a maze procedure and permanent pacemaker im-
plantation. Three years later, she underwent lumpectomy
and radiation for breast cancer.
Other history included multiple pulmonary emboli,
thoracic outlet syndrome, and neuropathic lower extremity
pain with right foot drop. The year before presentation, she
began to experience lower extremity edema, ascites, and
lack of appetite, and was found to have prosthetic tricuspid
valve stenosis and insufficiency. On presentation, she ex-
hibited New York Heart Association functional class IV
symptoms, was wheelchair-bound, and unable to undergo
exercise testing.
Her echocardiogram showed an ejection fraction of 55%,
2þ tricuspid regurgitation, and severe stenosis with peak
and mean gradients of 20 mm Hg and 16 mm Hg with
reversal of hepatic systolic flow. Coronary angiography re-
vealed no significant coronary artery disease. Pulmonary
function testing demonstrated restrictive dysfunction
(forced expiratory volume after 1 second of expiration
[FEV1] 0.88 L, 39% of predicted) and severely reduced
diffusing capacity of lung for carbon monoxide (DLCO
5.24 mL/min/mm Hg, 25% of predicted). Given her
advanced age and comorbidities, she was judged to be at
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intervention.
The procedure was performed under general anesthesia.
Our initial approach was via a 7-Fr sheath in the right
internal jugular vein. We placed a Berman catheter into
the right ventricle and measured a 15-mm Hg tricuspid
valve gradient by simultaneous right ventricle-right atrial
pressures. The Berman was advanced into the right
pulmonary artery and we exchanged the sheath for a
24-Fr Edwards sheath over an Amplatz extra stiff wire.
The Edwards Sapien delivery system with a mounted
26-mm valve (Edwards Lifesciences, Irvine, Calif) was
delivered across the Mosaic valve. Using fluoroscopy and
the post markers on the prosthetic valve as a reference point
and transesophageal echocardiography guidance, the valve
was deployed during rapid ventricular pacing. The Edwards
Sapien valve was seated at the tips of the Mosaic valve posts
(Figure 1). On observation over time, it appeared to migrate
in the ventricular direction. We did not feel confident about
its stability in this position and elected to place a second
valve. We were concerned about the risk of dislodging the
device on crossing the valve with a second device and
took preventive measures by placing a 20/6 Z-med balloon
into the RV via the internal jugular sheath to be usedery c May 2014
FIGURE 2. Advancing Sapien valve through Mosaic and Sapien valves
via the femoral vein with Z-med balloon in position via the internal jugular
vein.
Case Reportsemergently in the case of impending dislodgement of the
first device. Then, via a 24-Fr Edwards sheath the right
femoral vein, we placed a second Amplatz extra stiff wire
into the right pulmonary artery. We inserted another no.
26 Sapien valve into the Mosaic and Sapien valves
(Figure 2) without incident, removed the Z-med balloon,
and deployed the valve. After deployment, transesophageal
echocardiography confirmed a well-placed and seated valve
with minimal tricuspid regurgitation. The tricuspid valve
gradient decreased to 2 mm Hg and the central venous
pressure, which was 33 mmHg at the start of the procedure,
decreased to 13 mm Hg.
After the procedure, the patient was discharged home
with improved functional status, edema, and appetite.The Journal of Thoracic and CaCOMMENT
The first human percutaneous transcatheter tricuspid
valve-in-valve implantation was described by Van Garsse
and colleagues1 using an Edwards Sapien valve and internal
jugular access. Since then, transatrial and transfemoral
methods have been described as well as the use of the
Melody valve in this application. There are still less than
40 cases reported in the literature; tricuspid valve-in-valve
implantation is still in its infancy.2 The femoral approach
may be favored in cases of relatively vertically oriented
tricuspid valves,2 however, in general, crossing the valve
in this approach is believed to be more technically
challenging because of the acute angle the catheter must
take from the inferior vena cava through the valve to the
right ventricle.3 We accepted this technical challenge as
the risk of embolizing the first Sapien valve warranted
prophylactic maneuvers via the internal jugular vein.
Troubleshooting maneuvers during transatrial deploy-
ment have been described,4 however, to our knowledge,
this is the first description of valve-in-valve deployment
both via the internal jugular and femoral veins, along with
the prophylactic insertion of a right ventricular balloon.
We believe that it is important to report potential challenges
and their management as this technique continues to evolve
so that all who perform these procedures can benefit from
others’ experience. Since this case we have performed 1
additional successful tricuspid valve-in-valve replacement
through the femoral vein.
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